AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15513449
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone treatment followed by oral prednisone
Trial: 9537209
Drug: Diflunisal 500
RxNorm normalized name: diflunisal 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diflunisal 500 mg perorally twice a day for 7 days
Trial: 9537209
Drug: Dipyrone 500
RxNorm normalized name: dipyrone 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyrone 500 mg perorally three times a day for 7 days
Trial: 9398952
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg physostigmine
Trial: 1760167
Drug: IM ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM ranitidine 1 mg/kg (n = 15)
Trial: 1760167
Drug: IM ranitidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM ranitidine 2 mg/kg (n = 15)
Trial: 6114900
Drug: Pirenzepine (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (0.15 mg/kg) plus ranitidine (0.6 mg/kg)
Trial: 23114134
Drug: Bisphosphonates combined
RxNorm normalized name: methylene diphosphonate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonates combined with chemotherapy
Trial: 19208456
Drug: Tat vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tat vaccine (7.5microg, 15microg, or 30microg doses)
Trial: 17595890
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg ER (evening)
Trial: 17595890
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg ER (morning)
Trial: 17595890
Drug: Fluvastatin 80
RxNorm normalized name: fluvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 80 mg ER (morning and evening)
Trial: 15823775
Drug: Travoprost 0.004%
RxNorm normalized name: TRAVOPROST 0.004% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Travoprost 0.004% ophthalmic solution (opened group)
Trial: 15823775
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (sealed travoprost 0.004% ophthalmic solution)
Trial: 11590531
Drug: Newer drugs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Newer drugs in the NRTI class and nucleotide RT inhibitors
Trial: 11590531
Drug: Drug resistance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug resistance testing
Trial: 8509233
Drug: Alfacalcidol (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (6 micrograms daily for 6 months)
Trial: 31728713
Drug: Patisiran 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patisiran 0.3 mg/kg intravenously once every 3 weeks for 18 months
Trial: 29606543
Drug: ASP7991 [1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP7991 [1 mg, 18.5 kBq (500 nCi)]
Trial: 24469862
Drug: Low-dose control
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose control (audiobooks)
Trial: 16003451
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy (simvastatin) for primary prevention in individuals with TC level higher than 6.2 mmol/L
Trial: 16003451
Drug: Lipid-lowering therapy
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering therapy (simvastatin) for secondary prevention in individuals with TC level higher than 6.2 mmol/L
Trial: 16003451
Drug: Lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering treatment for all individuals with TC level higher than 6.2 mmol/L
Trial: 16003451
Drug: Lipid-lowering treatment
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid-lowering treatment for all individuals regardless of TC levels
Trial: 12204809
Drug: atorvastatin 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin 20, 40, and 80 mg/day
Trial: 12204809
Drug: simvastatin 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: simvastatin 20, 40, and 80 mg/day
Trial: 12204809
Drug: pravastatin 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 20, 40, and 80 mg/day
Trial: 12204809
Drug: lovastatin 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lovastatin 20, 40, and 80 mg/day
Trial: 12204809
Drug: fluvastatin 20,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluvastatin 20, 40, and 80 mg/day
Trial: 8631045
Drug: Cilazapril 2.5-5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 2.5-5.0 mg per day
Trial: 1671389
Drug: Met-GH infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Met-GH infusion (80 ng/kg.min)
Trial: 27321488
Drug: Ulinastatin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ulinastatin treatment (8×10^5 U, twice a day for 7 days)
Trial: 22270199
Drug: Moisturizing lotion
RxNorm normalized name: MOISTURIZING LOTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moisturizing lotion (Eucerin Lotion)
Trial: 19497591
Drug: BC +
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BC + 5 mg propranolol
Trial: 19497591
Drug: BC +
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BC + 10 mg propranolol
Trial: 15700851
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with vincristine (VCR), methotrexate (MTX), and doxorubicin (ADM)
Trial: 7915824
Drug: Cabergoline (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cabergoline (0.5 to 1.0 mg twice weekly)
Trial: 7915824
Drug: Bromocriptine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (2.5 to 5.0 mg twice daily)
Trial: 1102234
Drug: dl‐Fenfluramine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl‐Fenfluramine hydrochloride (240 mg)
Trial: 1102234
Drug: dl‐Fenfluramine hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dl‐Fenfluramine hydrochloride (60, 120 mg)
Trial: 1102234
Drug: d‐amphetamine sulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d‐amphetamine sulfate (20, 40 mg)
Trial: 31977520
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg dexamethasone
Trial: 21319380
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of canales sacralis drop with acupotomy dissolution
Trial: 16531710
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with UFT
Trial: 11045848
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (10^10 CFU) in enterocoated tablets twice a day for 6 months
Trial: 8615097
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg for 5 days
Trial: 8615097
Drug: Tenoxicam 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 40 mg for 5 days
Trial: 8615097
Drug: Morphine on
RxNorm normalized name: Morphine only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine on the day of operation and placebo for 4 days
Trial: 4009494
Drug: Intravenous nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous nicotine (0.75, 1.5 and 3.0 mg/10‐sec infusion)
Trial: 4009494
Drug: Inhaled nicotine
RxNorm normalized name: nicotine Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled nicotine (0.4, 1.4 and 2.9 mg estimated yield)
Trial: 30371791
Drug: BIM23B065 (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIM23B065 (1.5 mg)
Trial: 30371791
Drug: BIM23B065 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIM23B065 (multiple doses)
Trial: 30371791
Drug: BIM23B065 (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIM23B065 (multiple ascending doses)
Trial: 30094984
Drug: Electroacupuncture (EA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroacupuncture (EA) stimulation of bilateral Hegu(LI 4) and Sanyinjiao(SP 6) for 25 min, combined with medication (mifepristone and misoprostol tablets)
Trial: 30094984
Drug: Medication (mifepristone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (mifepristone and misoprostol tablets)
Trial: 20061873
Drug: Prolonged exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged exposure therapy plus cognitive restructuring
Trial: 17345556
Drug: Idursulfase (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idursulfase (0.5 mg/kg) administered weekly
Trial: 17345556
Drug: Idursulfase (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idursulfase (0.5 mg/kg) administered fortnightly
Trial: 17345556
Drug: Idursulfase (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idursulfase (0.5 mg/kg)
Trial: 2198233
Drug: Propranolol alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol alone (20-80 mg)
Trial: 2198233
Drug: Propranolol in
RxNorm normalized name: propranolol Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol in combination with dilazep (50 mg three times a day)
Trial: 2198233
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of propranolol and dilazep
Trial: 346219
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (high-dose methotrexate, adriamycin, and vincristine)
Trial: 30829668
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of phenylephrine at 0.25 µg/kg/min
Trial: 30829668
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of phenylephrine at 0.375 µg/kg/min
Trial: 30829668
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of phenylephrine at 0.5 µg/kg/min
Trial: 30829668
Drug: IV infusion
RxNorm normalized name: IV INFUSION SET (WINTHROP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of phenylephrine at 0.625 µg/kg/min
Trial: 30063658
Drug: Prophylactic phenylephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic phenylephrine infusion
Trial: 21756566
Drug: Exercise treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise treatment for shoulder pain (12-week at-home program)
Trial: 15565935
Drug: Budesonide (400microg)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (400microg) administered once daily via Turbuhaler
Trial: 15565935
Drug: Beclomethasone dipropionate
RxNorm normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone dipropionate (400microg) administered twice daily via metered-dose inhaler
Trial: 11221554
Drug: Client-centered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centered treatment (CCT)
Trial: 11221554
Drug: Client-centered treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Client-centered treatment (CCT) with additional behavioral exposure treatment
Trial: 8512828
Drug: Epirubicin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (30 mg m-2 weekly)
Trial: 8512828
Drug: Doxorubicin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (25 mg m-2 weekly)
Trial: 30412478
Drug: Anti-TNF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF therapy plus GPR program
Trial: 30412478
Drug: Anti-TNF and
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF and conventional exercise therapy
Trial: 26475844
Drug: Ginger (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (1,000 mg daily for 10 weeks)
Trial: 20485974
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group emphasized on daily oral hygiene.
Trial: 16238982
Drug: No cardiac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cardiac resynchronization therapy (Control)
Trial: 10085055
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR either alone or in combination
Trial: 10085055
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR and CVD 111 combination
Trial: 342041
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g cephaloridine intraincisionally
Trial: 19647066
Drug: Monovalent HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monovalent HPV type 16 vaccine
Trial: 17268408
Drug: Increased intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased intake of vegetables (400 g/day) and fruit (300 g/day) through a group-based behavioral program for 3 months
Trial: 11573627
Drug: Alphadolone (25-500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alphadolone (25-500 mg, n = 9)
Trial: 9626375
Drug: Oral loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral loading dose of carbamazepine 8 mg/kg in suspension form
Trial: 9626375
Drug: Oral loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral loading dose of carbamazepine 8 mg/kg in tablet form
Trial: 9626375
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (tablet and suspension)
Trial: 2899237
Drug: Halofantrine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine at 10 mg/kg for two doses
Trial: 2899237
Drug: Halofantrine at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Halofantrine at 8 mg/kg for three doses
Trial: 30130144
Drug: 12-week Iyengar
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week Iyengar Yoga intervention given twice weekly
Trial: 30130144
Drug: Twice-weekly 12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-weekly 12-week program of traditional exercise (e.g., walking, stationary cycling)
Trial: 23170990
Drug: Gemigliptin 50
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemigliptin 50 mg
Trial: 18641545
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg synthetic tetrahydrocannabinol (Marinol)
Trial: 16463153
Drug: High-dose methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methotrexate (MTX) infusion regimens (4-h vs 24-h infusion)
Trial: 16463153
Drug: MTX applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX applied as 24-h infusion in all patients with lymphoblastic lymphoma and anaplastic large cell lymphoma
Trial: 10897230
Drug: Self-treatment (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-treatment (not consulting a physician)
Trial: 8636549
Drug: Treatment delay
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment delay < 1 hour
Trial: 8636549
Drug: Treatment delay
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment delay > 90 minutes
Trial: 8636549
Drug: Time to
RxNorm normalized name: Overtime Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time to treatment increase
Trial: 30773968
Drug: Eltrombopag as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltrombopag as monotherapy (Arm A); starting dose 200 mg orally daily
Trial: 26490015
Drug: Physician education
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Physician education and audit/feedback on antibiotic prescribing quantity and quality
Trial: 24606090
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg PVI once daily
Trial: 24606090
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg PVI once daily
Trial: 24606090
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg PVI once daily
Trial: 24606090
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg PVI twice daily
Trial: 24606090
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg PVI twice daily
Trial: 24606090
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg PIO via im injection once daily
Trial: 24606090
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg PIO via im injection once daily
Trial: 24606090
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg PIO via im injection once daily
Trial: 22313739
Drug: Ginger (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (1.5 g/d in 3 divided doses every 8 hours) plus standard antiemetic regimen (granisetron plus dexamethasone)
Trial: 17684881
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy plus intravenous hydrocortisone (200 mg first, then 100 mg TID for 48 hours)
Trial: 17684881
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy (complete bed rest, hydration, acetaminophen and pethidine)
Trial: 10666547
Drug: Intramuscular capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular capsaicin 100 microg/1 ml
Trial: 10666547
Drug: Intramuscular capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular capsaicin 100 microg/20 microl
Trial: 10666547
Drug: Intradermal capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intradermal capsaicin 100 microg/20 microl
Trial: 10666547
Drug: Intramuscular capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular capsaicin 1 ml
Trial: 10666547
Drug: Intramuscular capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular capsaicin 20 microl
Trial: 1730811
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate injections (3 mg/kg.week, im)
Trial: 29771789
Drug: Raltegravir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 1200 mg once daily (QD)
Trial: 29771789
Drug: Raltegravir 400
RxNorm normalized name: raltegravir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir 400 mg twice daily (BID)
Trial: 25239225
Drug: Trabectedin 1.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 1.3 mg/m(2) once every 3 weeks (1/3 treatment arm)
Trial: 25239225
Drug: Trabectedin 0.58
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trabectedin 0.58 mg/m(2) every week for 3 of 4 weeks (3/4 treatment arm)
Trial: 15838067
Drug: Metformin, 850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin, 850 mg twice daily
Trial: 10713806
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily gentamicin (4 mg/kg)
Trial: 10713806
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily gentamicin (2.5 mg/kg)
Trial: 29438649
Drug: Cannabidiol as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cannabidiol as an anticonvulsant drug
Trial: 21943315
Drug: Telepsychiatry-based culturally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telepsychiatry-based culturally sensitive collaborative treatment (T-CSCT)
Trial: 23227679
Drug: Conventional acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional acupuncture therapy (4 weeks, 3-5 treatments per week)
Trial: 15124981
Drug: R-roscovitine (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-roscovitine (50, 100, 200, 400, or 800 mg)
Trial: 15124981
Drug: R-roscovitine (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-roscovitine (50, 100, 200, 400, or 800 mg) after breakfast
Trial: 11773168
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (cisplatin-based) followed by radical surgery (type III to V radical hysterectomy plus systematic pelvic lymphadenectomy)